Gapping up
In reaction to strong earnings/guidance:
- MRTN +4.2%, ETFC +3.5%, ISRG +3.3%, INDB +2.8%, KO +2.2%, STT +2.2%, SYF +1.9%, AXP +1.9%, QTNT +1.6% (announces positive Verification & Validation results for Extended Immunohematology Microarray; says prelim quarterly results reflect revenue higher than prior guidance), TEAM +0.8%, SLB +0.8%, .
Other news:
- VRCA +11.9% (presents positive data from three abstracts evaluating the efficacy and safety of VP-102 at the 2019 39th Annual Fall Clinical Dermatology Conference)
- ENDP +7.5% (continued strength)
- RIGL +7.5% (receives positive trend vote from CHMP for fostamatinib disodium hexahydrate (fostamatinib) for the treatment of chronic immune thrombocytopenia in adults) RDHL +7% (enters into strategic collaboration with Cosmo Pharmaceuticals -- includes private investment by Cosmo of $36.3 mln in RedHill at $7.00 per American Depositary Share)
- CSTL +5.7% (presents data supporting the ability of the DecisionDx-Melanoma gene expression profile test to identify T1 (tumor depth of 1 mm or less) melanoma patients at low risk for a positive sentinel lymph node)
- HEP +4.9% (expects to maintain its current distribution through 2020)
- PRTK +2.9% (withdraws MAA submission for NUZYRA)
- T +0.7% (AT&T lifting on possible Elliott Management resolution that includes strategic review)
Analyst comments:
- SNAP +3.2% (upgraded to Buy from Neutral at BofA/Merrill)
- NMRK +2.9% (resumed with a Buy at BofA/Merrill)
- RCL +1.7% (upgraded to Outperform from Neutral at Macquarie)
- TNDM +1.5% (initiated with a Buy at Guggenheim; tgt $76)
- APA +0.8% (upgraded to Neutral from Underperform at BofA/Merrill)